Pioglitazone

Pioglitazone is not a molecular target or receptor; rather, it is a small molecule drug classified as a thiazolidinedione that functions by selectively activating a molecular target: the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear receptor involved in regulating glucose and lipid metabolism in several tissues[2][5][7][8]. Pioglitazone is an oral antidiabetic agent from the thiazolidinedione drug class, used to treat type 2 diabetes mellitus as an adjunct to diet and exercise[1][3][5]. Its primary mode of action is as a selective agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma), thereby improving insulin sensitivity in tissues such as adipose tissue, muscle, and liver[2][5][7][8]. PPAR-gamma is a nuclear receptor and ligand-activated transcription factor that controls the transcription of genes involved in glucose and lipid metabolism[2][7][8]. Pioglitazone is itself not a receptor, enzyme, transporter, or canonical therapeutic target, but a drug that targets the PPAR-gamma receptor[2][5][7][8]. Common aliases/brand names for pioglitazone include Actos, Glustin, Zactos, and Pioglitazona (Spanish/Italian spelling)[3][8]. Safety concerns associated with pioglitazone use include risk of heart failure, bladder cancer, bone fracture, and fluid retention[3][5][8]. Mechanism of action: Pioglitazone binds PPAR-gamma, leading to enhanced insulin sensitivity, reduced hepatic glucose production, and altered lipid profiles[2][5][7][8]. Summary of error: - The query lists pioglitazone as a "target," but it is not a biological target or receptor; it is a drug. The true molecular target of pioglitazone is PPAR-gamma[2][7]. If you need details about the actual molecular target of pioglitazone, request information for peroxisome proliferator-activated receptor gamma (PPAR-gamma), not the drug itself.

Other names

ActosGlustinZactosPioglitazona (non-English spelling)